Abstract
1. Norfloxacin was administered as two daily 400 mg oral doses to eight elderly patients requiring treatment for urinary tract infections. Blood specimens were obtained for pharmacokinetic profiles following the first and fifteenth doses. Further specimens were obtained before each morning's dose of norfloxacin. Specimens of urine were obtained to ascertain if adequate antimicrobial concentrations were reached in these patients with diminished renal function. 2. Norfloxacin half-life was consistent with that expected in mild renal impairment and was not different between the first and fifteenth doses. Based on ratios of AUC values, accumulation is probably related to renal function, being greatest for creatinine clearance values below 30 ml min-1. 3. On the great majority of occasions, the urinary concentrations of norfloxacin exceeded 20 micrograms ml-1. On days 2-7, the mean percentage 12 h renal elimination of norfloxacin was 18.6 +/- 1.47 (mean of 82 separate observations). Norfloxacin 400 mg twice daily was well tolerated in this group of elderly patients and produced adequate antimicrobial concentrations in urine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boppana V. K., Swanson B. N. Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography. Antimicrob Agents Chemother. 1982 May;21(5):808–810. doi: 10.1128/aac.21.5.808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Deaney N. B., Vogel R., Vandenburg M. J., Currie W. J. Norfloxacin in acute urinary tract infections. Practitioner. 1984 Jan;228(1387):111–117. [PubMed] [Google Scholar]
- Eandi M., Viano I., Di Nola F., Leone L., Genazzani E. Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage. Eur J Clin Microbiol. 1983 Jun;2(3):253–259. doi: 10.1007/BF02029528. [DOI] [PubMed] [Google Scholar]
- Guerra J. G., Falconi E., Palomino J. C., Benavente L., Antunez de Mayolo E. Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections. Eur J Clin Microbiol. 1983 Jun;2(3):260–265. doi: 10.1007/BF02029529. [DOI] [PubMed] [Google Scholar]
- Hughes P. J., Webb D. B., Asscher A. W. Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results. J Antimicrob Chemother. 1984 May;13 (Suppl B):55–57. doi: 10.1093/jac/13.suppl_b.55. [DOI] [PubMed] [Google Scholar]
- King A., Warren C., Shannon K., Phillips I. In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother. 1982 Apr;21(4):604–607. doi: 10.1128/aac.21.4.604. [DOI] [PMC free article] [PubMed] [Google Scholar]